Citius Pharmaceuticals, Inc. (CTXR) – What Are Investment Firms Saying About This Stock?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has been assigned a consensus recommendation of “Hold” from the five brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $5.00.

A number of research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Monday, September 21st. HC Wainwright restated a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Finally, Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th.

Hedge Funds Weigh In On Citius Pharmaceuticals

An institutional investor recently bought a new position in Citius Pharmaceuticals stock. BlackRock Inc. bought a new stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned 0.25% of Citius Pharmaceuticals as of its most recent SEC filing. 16.88% of the stock is owned by institutional investors.

Citius Pharmaceuticals Trading Down 1.3%

NASDAQ CTXR opened at $0.49 on Thursday. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.40 and a current ratio of 0.84. The stock has a 50 day simple moving average of $0.59 and a two-hundred day simple moving average of $0.63. The stock has a market cap of $13.53 million, a P/E ratio of -0.30 and a beta of 1.00.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. On average, analysts forecast that Citius Pharmaceuticals will post -2.03 earnings per share for the current year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for oncology and critical care. The company’s pipeline has included therapies intended to address unmet medical needs in hospital and cancer-care settings.

Citius’ lead oncology product is LYMPHIR (denileukin diftitox-cxdl), an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.